Search

Your search keyword '"Laurenz, T."' showing total 6 results
Start Over Author "Laurenz, T."
6 results on '"Laurenz, T."'

1. New high-tech flexible networks for the monitoring of deep-sea ecosystems

Author

Aguzzi, J., Chatzievangelou, D., Marini, S., Fanelli, E., Danovaro, R., Flogel, S., Juanes, F., De Leo, F., Del Rio, J., Laurenz, T., Costa, C., Riccobene, G., Tamburini, C., Lefevre, D., Gojak, C., Poulain, P-M., Favali, P., Griffa, A., Purser, A., Cline, D., Edgington, D., Navarro, J., Stefanini, S., Hondt, S. D, Priede, I. G., Rountree, R., and Company, J. B.

Subjects
Physics - Instrumentation and Detectors, Quantitative Biology - Populations and Evolution
Abstract

Increasing interest in the acquisition of biotic and abiotic resources from within the deep sea (e.g. fisheries, oil-gas extraction, and mining) urgently imposes the development of novel monitoring technologies, beyond the traditional vessel-assisted, time-consuming, high-cost sampling surveys. The implementation of permanent networks of seabed and water-column cabled (fixed) and docked mobile platforms is presently enforced, to cooperatively measure biological features and environmental (physico-chemical) parameters. Video and acoustic (i.e. optoacoustic) imaging are becoming central approaches for studying benthic fauna (e.g. quantifying species presence, behaviour, and trophic interactions) in a remote, continuous, and prolonged fashion. Imaging is also being complemented by in situ environmental-DNA sequencing technologies, allowing the traceability of a wide range of organisms (including prokaryotes) beyond the reach of optoacoustic tools. Here, we describe the different fixed and mobile platforms of those benthic and pelagic monitoring networks, proposing at the same time an innovative roadmap for the automated computing of hierarchical ecological information of deep-sea ecosystems (i.e. from single species abundance and life traits, to community composition, and overall biodiversity), Comment: 56 pages, 4 figures This document is the unedited Author's version of a Submitted Work that was subsequently accepted for publication in Environmental Science and Technology, copyright American Chemical Society after peer review. To access the final edited and published work see Journal Reference

Published
2022
Full Text
View/download PDF

2. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

Author

Laurenz T. Fischer, Daniel A. Hochfellner, Lisa Knoll, Tina Pöttler, Julia K. Mader, and Felix Aberer

Subjects
PCSK9 inhibitor therapy, Lipid lowering therapy, Real world data, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background The lipid-lowering and positive cardiovascular effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors was shown in several studies, hence, they are more widely used in the lipid-lowering management of individuals with high cardiovascular risk. As real-world data are still scarce, specifically in patients with type 2 diabetes (T2D), the aim of this retrospective analysis was to investigate the efficacy of PCSK9 inhibitors in lowering low-density lipoprotein cholesterol (LDL-C) in an outpatient clinic of a tertiary care center in routine care. Methods A retrospective analysis of data extracted from the electronic patient record was performed. Patients who were routinely prescribed with PCSK9 inhibitor therapy (alirocumab or evolocumab) during the years 2016 and 2019 were included in the analysis. Characteristics of the patient population, the effects on LDL-C and HbA1c levels as well as subsequent cardiovascular events were assessed over an observation period of 18 months. Results We identified 237 patients treated with PCSK9 inhibitors between January 2016 and September 2019. Almost all patients (97.5%) received PCSK9 inhibitors for secondary prevention. 26.2% of the population had a concomitant diabetes diagnosis. Intolerance to statins (83.1%), ezetimibe (44.7%) or both agents (42.6%) was reported frequently. Three months after initiation of PCSK9 inhibitor therapy, 61.2% of the patients achieved LDL-C levels 54 mmol/mol) had a higher reduction in LDL-C but still were more likely to subsequent cardiovascular events. Conclusions Significant reductions in LDL-C and a high percentage of patients achieving recommended treatment targets were observed. The percentage of patients with T2D meeting recommended LDL-C targets was higher than in those without T2D. Still some patients did not achieve LDL-C levels as recommended in current guidelines. Special attention to the characteristics of these patients is required in the future to enable achievement of treatment goals and avoid adverse cardiovascular outcomes.

Published
2021
Full Text
View/download PDF

4. Metabolic Effects of PCSK9 Inhibitors in a Tertiary Care Center – Real World Data

Author

Julia K Mader, Lisa Knoll, Felix Aberer, Laurenz T. Fischer, Daniel A. Hochfellner, and Tina Pöttler

Subjects
business.industry, Metabolic effects, Medicine, Center (algebra and category theory), Medical emergency, business, PCSK9 Inhibitors, medicine.disease, Tertiary care, Real world data
Abstract

BackgroundThe lipid-lowering and positive cardiovascular effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors was shown in several studies, hence, they are more widely used in the lipid-lowering management of patients with high cardiovascular risk. As real-world data are still scarce, the aim of this retrospective analysis was to investigate the efficacy of PCSK9 inhibitors in lowering low-density lipoprotein cholesterol (LDL-C) in an outpatient clinic of a tertiary care center in routine care.MethodsA retrospective analysis of data extracted from the electronic patient record was performed. Patients who were routinely prescribed with PCSK9 inhibitor therapy (Alirocumab or Evolocumab) during the years 2016 and 2019 were included in the analysis. Characteristics of the patient population, the effects on LDL-C and HbA1c levels were assessed over the course of treatment.ResultsWe identified 237 patients treated with PCSK9 inhibitors between January 2016 and September 2019. Almost all patients (97.5%) received PCSK9 inhibitors for secondary prevention. Comorbidities at baseline included: arterial hypertension (68.8%), diabetes mellitus (25.3%), smoking (5.9%). Vascular disease at baseline was present as follows: coronary heart disease (74.7%), history of stroke or transient ischemic attack (13.5%), carotid artery disease (30.8%), peripheral artery disease (18.1%), chronic kidney disease (9.7%), history of percutaneous coronary intervention (46.4%), history of coronary artery bypass surgery (16.0%).Intolerance to statins (83.1%), ezetimibe (44.7%), and both agents was reported frequently (42.6%).Six to nine months after initiation of PCSK9 inhibitor therapy, 61.7% of the patients achieved LDL-C levels ≤70 mg/dl, and 44.3% achieved LDL-C levels ≤55 mg/dl. The median LDL-C was lowered from 141 (IQR 117 - 188) mg/dl at baseline, to 60 (43 - 91) mg/dl (6 to 9 months) and 67 (44 - 89) mg/dl (12 to 18 months) indicating a reduction of LDL-C as follows: -54.9% (interquartile range (IQR) 44.4 – 57.3) after 6 to 9 months, -53.2% (IQR 42.6 – 67.1) after 12 to 18 months from baseline. ConclusionsSignificant reductions in LDL-C and a high percentage of patients achieving recommended treatment targets were observed. Still some patients did not achieve LDL-C levels recommended in current guidelines. Special attention to the characteristics of these patients is required in the future to enable achievement of treatment goals and avoid adverse cardiovascular outcomes.

Published
2021

5. Additional file 1 of Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

Author

Fischer, Laurenz T., Hochfellner, Daniel A., Knoll, Lisa, Pöttler, Tina, Mader, Julia K., and Aberer, Felix

Abstract

Additional file 1: Table S1. Cardiovascular disease at baseline (by medical condition). Data are number of patients (% from subgroup). Table S2. LDL-C levels over time of the overall cohort and by PCSK9 inhibitor agent (A) and according to diabetes status (B). Data are median (IQR). *P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time-point. Table S3. Triglyceride levels over time of the overall cohort and by PCSK9 inhibitor (A) and according to diabetes status (B). Data are median (IQR). *P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time-point. Table S4. HDL cholesterol levels over time of the overall cohort and by PCSK9 inhibitor agent (A) and diabetes status (B). Data are median (IQR). *P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time-point. Table S5. Lipoprotein(a) levels and follow-up measurement of the overall cohort, by PCSK9 inhibitor agent and by diabetes status. Data are median (IQR). *P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time. Only patients with follow-up data for Lp(a) were included in the analysis. † First performed follow-up measurement after initiation of PCSK9 inhibitor therapy was included in the analysis. Table S6. HbA1c levels over time of the overall cohort, without and with diabetes mellitus at baseline. Data are median (IQR). * P-values were calculated by using the Wilcoxon signed-rank test and refers to the comparisons of laboratory data between baseline and defined time-point.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results